VIA Medical neonatal blood gas and chemistry monitor system launch expected in spring of 1998.
This article was originally published in The Gray Sheet
VIA MEDICAL NEONATAL BLOOD GAS AND CHEMISTRY MONITOR LAUNCH NEXT SPRING for use in neonatal intensive care units is anticipated by the company. A similar adult version of the portable system, also intended for near-real-time, point-of-care bedside blood gas and chemistry monitoring, commenced U.S. shipments Dec. 1 at a list price of $7,995, the firm says. Disposable sensors used with the device, which last up to three days, list for $165 each. The neonatal version of the system will be priced at a slight premium to the adult version but final pricing has not yet been set, according to the company.
You may also be interested in...
Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.